--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About SEPN20260220C30
Biological Technology
Septerna, Inc., was incorporated in Delaware in December 2019 under the name GPCR NewCo, Inc. In June 2021, they changed their name to Septerna, Inc. The company is a clinical-stage biotechnology company that has ushered in a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, powered by its proprietary Native Complex PlatformTM. Their industrial-scale platform aims to unlock the full potential of GPCR therapies and discover and develop their deep pipeline of product candidates, initially focusing on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
